Mallinckrodt plc provided financial guidance for its fiscal year ending September 26, 2014. For fiscal 2014, the company's annual net sales are expected to be in the range of $2.15 billion to $2.25 billion on an operational basis, which excludes the impact of fluctuations in foreign currency exchange rates. Net sales for the Specialty Pharmaceuticals segment are expected to be in the range of $1.22 billion to $1.27 billion.

This forecast includes net sales of at least $120 million for the company's generic version of Concerta(R) (Methylphenidate HCI) extended-release tablets USP (CII). Net sales for the Global Medical Imaging segment are expected to be in the range of $885 million to $930 million. Also for fiscal 2014, the company expects adjusted diluted earnings per share (EPS) to be in the range of $2.45 to $2.65.

The non-GAAP effective tax rate is expected to be between 26% and 29%. Capital expenditures are forecasted to be in the range of $140 million to $160 million.